Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy : a European MCL intergroup study
The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209.
| Errataetall: |
CommentIn: Blood. 2010 Apr 22;115(16):3180-1. - PMID 20413661 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Blood - 115(2010), 16 vom: 22. Apr., Seite 3215-23 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pott, Christiane [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.05.2010 Date Revised 20.10.2021 published: Print-Electronic ClinicalTrials.gov: NCT00209209, NCT00209222 CommentIn: Blood. 2010 Apr 22;115(16):3180-1. - PMID 20413661 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood-2009-06-230250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM19396385X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM19396385X | ||
| 003 | DE-627 | ||
| 005 | 20231223195745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood-2009-06-230250 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0647.xml |
| 035 | |a (DE-627)NLM19396385X | ||
| 035 | |a (NLM)20032498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pott, Christiane |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy |b a European MCL intergroup study |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00209209, NCT00209222 | ||
| 500 | |a CommentIn: Blood. 2010 Apr 22;115(16):3180-1. - PMID 20413661 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within 2 randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment, 106 of 190 evaluable patients (56%) achieved a molecular remission (MR) based on blood and/or bone marrow (BM) analysis. MR resulted in a significantly improved response duration (RD; 87% vs 61% patients in remission at 2 years, P = .004) and emerged to be an independent prognostic factor for RD (hazard ratio = 0.4, 95% confidence interval, 0.1-0.9, P = .028). MR was highly predictive for prolonged RD independent of clinical response (complete response [CR], complete response unconfirmed [CRu], partial response [PR]; RD at 2 years: 94% in BM MRD-negative CR/CRu and 100% in BM MRD-negative PR, compared with 71% in BM MRD-positive CR/CRu and 51% in BM MRD-positive PR, P = .002). Sustained MR during the postinduction period was predictive for outcome in MCL Younger after autologous stem cell transplantation (ASCT; RD at 2 years 100% vs 65%, P = .001) and during maintenance in MCL Elderly (RD at 2 years: 76% vs 36%, P = .015). ASCT increased the proportion of patients in MR from 55% before high-dose therapy to 72% thereafter. Sequential MRD monitoring is a powerful predictor for treatment outcome in MCL. These trials are registered at www.clinicaltrials.gov as #NCT00209222 and #NCT00209209 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Aged, 80 and over | |
| 650 | 4 | |a Antineoplastic Combined Chemotherapy Protocols | |
| 650 | 4 | |a Cell Separation | |
| 650 | 4 | |a Combined Modality Therapy | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Flow Cytometry | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Immunohistochemistry | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Lymphoma, Mantle-Cell | |
| 650 | 4 | |a MRD | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Middle Aged | |
| 650 | 4 | |a Neoplasm Staging | |
| 650 | 4 | |a Neoplasm, Residual | |
| 650 | 4 | |a Polymerase Chain Reaction | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a RQ-PCR | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Treatment Outcome | |
| 650 | 4 | |a autologous stem cell transplantation | |
| 650 | 4 | |a immunochemotherapy | |
| 650 | 4 | |a mantle cell lymphoma | |
| 650 | 4 | |a methods | |
| 650 | 4 | |a minimal residual disease | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a therapeutic use | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Hoster, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Delfau-Larue, Marie-Helene |e verfasserin |4 aut | |
| 700 | 1 | |a Beldjord, Kheira |e verfasserin |4 aut | |
| 700 | 1 | |a Böttcher, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Asnafi, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Plonquet, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Siebert, Reiner |e verfasserin |4 aut | |
| 700 | 1 | |a Callet-Bauchu, Evelyne |e verfasserin |4 aut | |
| 700 | 1 | |a Andersen, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a van Dongen, Jacques J M |e verfasserin |4 aut | |
| 700 | 1 | |a Klapper, Wolfram |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Françoise |e verfasserin |4 aut | |
| 700 | 1 | |a Ribrag, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a van Hoof, Achiel L |e verfasserin |4 aut | |
| 700 | 1 | |a Trneny, Marek |e verfasserin |4 aut | |
| 700 | 1 | |a Walewski, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Dreger, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Unterhalt, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Hiddemann, Wolfgang |e verfasserin |4 aut | |
| 700 | 1 | |a Kneba, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Kluin-Nelemans, Hanneke C |e verfasserin |4 aut | |
| 700 | 1 | |a Hermine, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Macintyre, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Dreyling, Martin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 115(2010), 16 vom: 22. Apr., Seite 3215-23 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2010 |g number:16 |g day:22 |g month:04 |g pages:3215-23 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood-2009-06-230250 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2010 |e 16 |b 22 |c 04 |h 3215-23 | ||